Collaborative Research Agreement Sample Contracts

BioXcel Therapeutics, Inc. – Collaborative Research Agreement (February 26th, 2018)

THIS COLLABORATIVE RESEARCH AGREEMENT (this Agreement) is made and entered into as of August 27th, 2017 (Effective Date) between BIOXCEL THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 780 East Main Street, Branford, CT 06405 (BTI) and NEKTAR THERAPEUTICS, a Delaware corporation, having its principal place of business at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (Nektar). Each of Nektar and BTI may be referred to herein as a Party or collectively as the Parties.

Endra Inc. – Amendment 2 to the Collaborative Research Agreement Between General Electric Company and Endra Life Sciences Inc. (February 5th, 2018)

This Amendment 2 to the Collaborative Research Agreement ("Amendment"), effective as of the last date of signing below ("Effective Date"), amends the TERM between General Electric ("GE") & ENDRA Life Sciences Inc. ("Endra"), which became effective as of April 22, 2016, as amended by that certain Amendment 1 to the Collaborative Research Agreement, dated April 21, 2017 ("Agreement").

Scythian Biosciences Corp. – Amendment to Collaborative Research Agreement (October 18th, 2017)

This Amendment is hereby made on this 6th day of October 2017. The Parties hereto have previously entered into a COLLABORATIVE RESEARCH AGREEMENT (the "Agreement") on July 25, 2016 between Scythian Biosciences Inc. which through amalgamation is now Scythian Biosciences Corp. (the "Company"), and University of Miami (the "Institution"). Each of the Company and Institution are sometimes referred to herein as a "Party" or, jointly, as the "Parties."

Scythian Biosciences Corp. – Amendment No.1 to Collaborative Research Agreement (August 21st, 2017)

THIS AMENDMENT TO the Collaborative Research Agreement ("Amendment") is hereby made and entered into this 10th day of February 2017, by and between the University of Miami ("Institution") and Scythian Biosciences, Inc. ("Company").

Scythian Biosciences Corp. – Collaborative Research Agreement (August 21st, 2017)

THIS COLLABORATIVE RESEARCH AGREEMENT (the "Agreement") is entered into as of the 25th day of July, 2016 (the "Effective Date") by and between Scythian Biosciences Inc., having offices at Scythian Biosciences Inc. 101-1865 Dilworth Drive #737 Kelowna, BC V1Y 9Tl 250-864-2740 Canada ("Company"), and University of Miami, a not-for-profit corporation having an office at 1320 S. Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the "Institution"). Each of Company and Institution are sometimes referred to herein as a "Partv" or, jointly, as the "Parties."

Zomedica Pharmaceuticals Corp. – Collaborative Research Agreement (April 21st, 2017)

THIS COLLABORATIVE RESEARCH AGREEMENT ("Agreement"), is made the 3rd day of January, 2017 (the "Effective Date"), by and between Celsee Diagnostics, Inc. whose address is 4670l Commerce Center Drive, Plymouth, MI 48170 ("Celsee") and Zomedica Pharmaceuticals Corp. whose head office address is 3928 Varsity Drive, Ann Arbor, MI 48018 ("Zomedica") (Celsee and Zomedica are each a "Party" and collectively the "Parties").

Zomedica Pharmaceuticals Corp. – Collaborative Research Agreement (March 9th, 2017)

THIS COLLABORATIVE RESEARCH AGREEMENT ("Agreement"), is made the 3rd day of January, 2017 (the "Effective Date"), by and between Celsee Diagnostics, Inc. whose address is 4670l Commerce Center Drive, Plymouth, MI 48170 ("Celsee") and Zomedica Pharmaceuticals Corp. whose head office address is 3928 Varsity Drive, Ann Arbor, MI 48018 ("Zomedica") (Celsee and Zomedica are each a "Party" and collectively the "Parties").

Endra Inc. – Collaborative Research Agreement (November 21st, 2016)

THIS AGREEMENT is made as of April 22, 2016 ("Effective Date") by and between General Electric Company, acting through its GE Healthcare business and Global Research unit ("GE"), and ENDRA Inc. a Delaware corporation having its principal place of business at Ann Arbor, MI ("ENDRA").

AquaBounty Technologies, Inc. – Collaborative Research Agreement (November 7th, 2016)

This COLLABORATIVE RESEARCH AGREEMENT (this Agreement) is made and entered into as of March 22, 2012, by and between Aqua Bounty Canada Inc. (the Company), a Newfoundland corporation having registered offices at P.O. Box 2430, St. Johns, Newfoundland, Canada, A1C 6E7, and Tethys Aquaculture Canada, Inc. (the Collaborator), a Canadian corporation with offices at 0718 Bay Fortune, RR No. 4, Souris, PEI, Canada, C0A 2B0. The Company and the Collaborator are sometimes referred to in this Agreement together as the Parties or individually as a Party.

Endra Inc. – Collaborative Research Agreement (September 21st, 2016)

THIS AGREEMENT is made as of April 22, 2016 ("Effective Date") by and between General Electric Company, acting through its GE Healthcare business and Global Research unit ("GE"), and ENDRA Inc. a Delaware corporation having its principal place of business at Ann Arbor, MI ("ENDRA").

Protokinetix Inc – Collaborative Research Agreement (August 15th, 2016)

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at 103 - 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 ("UBC") AND VANCOUVER COASTAL HEALTH AUTHORITY, a regional health board established under the Health Authorities Act (British Columbia) having its research administrative offices at Room 3665 - 910 West 10th Avenue, Jim Pattison Pavilion North, VGH, Vancouver, British Columbia, V5Z 1M9 ("VCHA")

Endra Inc. – Collaborative Research Agreement (August 9th, 2016)

THIS AGREEMENT is made as of April 22, 2016 ("Effective Date") by and between General Electric Company, acting through its GE Healthcare business and Global Research unit ("GE"), and ENDRA Inc. a Delaware corporation having its principal place of business at Ann Arbor, MI ("ENDRA").

Inovio Biomedical Corporation – Collaborative Research Agreement (May 9th, 2016)

This COLLABORATIVE RESEARCH AGREEMENT (the "Agreement") is made as of the 14th day of March, 2016 (the "Effective Date") by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a Commonwealth of Pennsylvania nonprofit corporation ("Wistar") and INOVIO PHARMACEUTICALS, INC., a corporation organized under the laws of Delaware ("Collaborator").

Inovio Biomedical Corporation – Collaborative Research Agreement (May 9th, 2016)

This COLLABORATIVE RESEARCH AGREEMENT (the "Agreement") is made as of the 14th day of March, 2016 (the "Effective Date") by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a Commonwealth of Pennsylvania nonprofit corporation ("Wistar") and INOVIO PHARMACEUTICALS, INC., a corporation organized under the laws of Delaware ("Collaborator").

Kraig Biocraft Laboratories, Inc – INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT Between Kraig Biocraft Laboratories, Inc. (SPONSOR) and the University of Notre Dame Du Lac (NOTRE DAME) (March 31st, 2015)
Kraig Biocraft Laboratories, Inc – INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT Between Kraig Biocraft Laboratories, Inc. (SPONSOR) and the University of Notre Dame Du Lac (NOTRE DAME) (January 30th, 2015)

SPONSOR grants to NOTRE DAME and NOTRE DAME accepts support for basic research investigations under the direction of Dr. Malcolm Fraser at College of Science in the department of Biological Science as described in the attached Statement of Work (Attachment A). NOTRE DAME undertakes this research in furtherance of its goal of seeking new knowledge.

Nuvilex Inc – Collaborative Research Agreement Between University of Veterinary Medicine Vienna and Nuvilex, Inc. (October 17th, 2014)

*** Certain confidential information contained in this document, marked by brackets, has been omitted and filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

AquaBounty Technologies, Inc. – Collaborative Research Agreement (July 23rd, 2014)

This COLLABORATIVE RESEARCH AGREEMENT (this Agreement) is made and entered into as of March 22, 2012, by and between Aqua Bounty Canada Inc. (the Company), a Newfoundland corporation having registered offices at P.O. Box 2430, St. Johns, Newfoundland, Canada, A1C 6E7, and Tethys Aquaculture Canada, Inc. (the Collaborator), a Canadian corporation with offices at 0718 Bay Fortune, RR No. 4, Souris, PEI, Canada, C0A 2B0. The Company and the Collaborator are sometimes referred to in this Agreement together as the Parties or individually as a Party.

Hepatocyte Collaborative Research Agreement (June 3rd, 2013)

This Collaborative Research Agreement is entered into as of May 16, 2011, (the "Effective Date") by and between on the one hand, Hoffmann-La Roche Inc. located at 340 Kingsland Street, Nutley, New Jersey 07110 ("Roche") and, on the other hand, Cellular Dynamics International, Inc. located at 525 Science Drive, Madison, WI 53711 ("CDI")

Hepatocyte Collaborative Research Agreement (April 10th, 2013)

This Collaborative Research Agreement is entered into as of May 16, 2011, (the "Effective Date") by and between on the one hand, Hoffmann-La Roche Inc. located at 340 Kingsland Street, Nutley, New Jersey 07110 ("Roche") and, on the other hand, Cellular Dynamics International, Inc. located at 525 Science Drive, Madison, WI 53711 ("CDI")

Collaborative Research Agreement Between Celator Technologies Incorporated and British Columbia Cancer Agency (November 13th, 2012)

BRITISH COLUMBIA CANCER AGENCY, having its administrative offices at 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6 (BCCA)

Kraig Biocraft Laboratories, Inc – INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT Between Kraig Biocraft Laboratories, Inc. (SPONSOR) and the University of Notre Dame Du Lac (NOTRE DAME) (May 28th, 2010)
Kraig Biocraft Laboratories, Inc – Intellectual Property/Collaborative Research Agreement (April 15th, 2010)
Amendment No. 2 to the Amended and Restated Collaborative Research Agreement (April 5th, 2010)

THIS AMENDMENT NO. 2 TO THE AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Second Amendment) is entered into and effective as of February 23, 2010 (the Second Amendment Date) by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002, (Shell) and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Amended and Restated Collaborative Research Agreement (April 5th, 2010)

This Series D Preferred Stock Purchase Agreement (the Agreement) is made and entered into as of August 22, 2006, by and among Codexis, Inc., a Delaware corporation (the Company), and the purchasers, severally and not jointly, listed on Exhibit A hereto, each of which is herein referred to as a Purchaser and all of which are collectively referred to herein as the Purchasers.

Amendment to the Amended and Restated Collaborative Research Agreement (April 5th, 2010)

This Series F Preferred Stock Purchase Agreement (the Agreement) is made and entered into as of March 4, 2009, by and among Codexis, Inc., a Delaware corporation (the Company), and the purchasers, severally and not jointly, listed on Exhibit A hereto, each of which is herein referred to as a Purchaser and all of which are collectively referred to herein as the Purchasers.

Amendment No. 2 to the Amended and Restated Collaborative Research Agreement (February 26th, 2010)

THIS AMENDMENT NO. 2 TO THE AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Second Amendment) is entered into and effective as of February 23, 2010 (the Second Amendment Date) by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002, (Shell) and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Amended and Restated Collaborative Research Agreement (January 14th, 2010)

THIS AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Amended and Restated Research Agreement or the Agreement) is entered into as of the Execution Date and effective as of November 1, 2006 (the Effective Date), by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002 (Shell), and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Amendment to the Amended and Restated Collaborative Research Agreement (January 14th, 2010)

THIS AMENDMENT TO THE AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Amendment) is entered into and effective as of March 4, 2009 (the Amendment Date) by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002, (Shell) and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Amended and Restated Collaborative Research Agreement (August 4th, 2008)

THIS AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Amended and Restated Research Agreement or the Agreement) is entered into as of the Execution Date and effective as of November 1, 2006 (the Effective Date), by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002 (Shell), and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Amended and Restated Collaborative Research Agreement (April 14th, 2008)

THIS AMENDED AND RESTATED COLLABORATIVE RESEARCH AGREEMENT, together with exhibits and schedules attached hereto, (the Amended and Restated Research Agreement or the Agreement) is entered into as of the Execution Date and effective as of November 1, 2006 (the Effective Date), by and between Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002 (Shell), and Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063 (Codexis). Shell and Codexis may each be referred to herein individually as a Party or, collectively, as the Parties.

Renovis, Inc. – Extensionamendment a to the Collaborative Research Agreement (May 9th, 2007)

This AMENDMENT A to the COLLABORATIVE RESEARCH AGREEMENT of June 28, 2005 (the Research Agreement) for the extension through the Third Commitment Year of the research term is entered into as of March 30, 2007 between:

Viragen Inc – COLLABORATIVE RESEARCH AGREEMENT (SK#6624) Effective on the 1st Day of February 2002, (July 31st, 2006)

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (hereinafter SKI), a not-for-profit corporation of the State of New York having offices at 1275 York Avenue, New York, NY 10021, and

Somanta Pharmaceuticals Inc. – Contract (July 19th, 2006)

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH [CONFIDENTIAL TREATMENT REQUESTED]. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Australian Research Council Linkage Grant Collaborative Research Agreement (April 25th, 2006)

A party must not assign its rights or obligations under this agreement without the prior written consent of the other party.